BIO-Europe Spring® 2014: Who will finance early stage drug discovery?

March 27, 2014
Common wisdom holds that it is getting harder and harder to find funding for drug discovery—yet financing data show that private rounds for companies whose lead programs are in preclinical development and earlier have been steadily rising since the meltdown. On top of that, big pharma is increasingly partnering directly with academics on discovery research, as well as participating in regional incubators that support early stage startups. For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/484
Previous Video
BIO-Europe Spring® 2014: The personalized therapy challenge
BIO-Europe Spring® 2014: The personalized therapy challenge

Very few companies have the in-house expertise to understand and identify all of the relevant biomarkers re...

Next Video
BIO-Europe Spring® 2014: From pariah to darling: Biopharma finally courts immunotherapies
BIO-Europe Spring® 2014: From pariah to darling: Biopharma finally courts immunotherapies

Immuno-oncology is suddenly the most talked about approach for changing the treatment paradigm of cancer, t...